Dexcom Q2 ’23 Earnings
Dexcom hosted its Q2 ‘23 earnings (press release; slides) and provided updates across its business. Of note, management highlighted that Dexcom had the highest YOY revenue growth recorded in company history at +26% ($871M) in Q2 ’23. As such, the company has increased its revenue guidance to $3.50-3.55B from $3.40-3.51B. Similar to commentary from Dexcom’s ADA 2023 investor event, management provided updates to the ongoing G7 US and OUS launches and reminded of plans to launch a 15-day sensor for people not on insulin in 2024 (previous FENIX insight). Below, FENIX provides highlights and insights from the call.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.